AIM ImmunoTech Files Proxy Statement

Ticker: AIM · Form: DEFA14A · Filed: Nov 4, 2024 · CIK: 946644

Sentiment: neutral

Topics: proxy-statement, regulatory-filing

TL;DR

AIM ImmunoTech filed proxy docs, no fee. Shareholders get info.

AI Summary

AIM ImmunoTech Inc. filed a DEFA14A on November 4, 2024, attaching a press release. The filing is related to proxy materials and indicates no fee was required for this submission. The company, formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida.

Why It Matters

This filing provides shareholders with important information regarding company governance and upcoming decisions, allowing them to participate in the company's direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing (DEFA14A) and does not contain new financial or operational disclosures that would inherently increase risk.

Key Players & Entities

FAQ

What type of filing is this?

This is a DEFA14A, a Definitive Additional Materials filing, which includes a press release issued by AIM ImmunoTech Inc. on November 4, 2024.

When was the press release issued?

The press release attached to this filing was issued on November 4, 2024.

Was there a filing fee for this document?

No, the filing indicates that no fee was required for this submission.

What is the company's former name?

The company's former name was Hemispherx Biopharma Inc., with a date of name change on June 14, 1995.

Where is AIM ImmunoTech Inc. located?

AIM ImmunoTech Inc. is located at 2117 SW Highway 484, Ocala, Florida, 32801.

Filing Stats: 4,421 words · 18 min read · ~15 pages · Grade level 11.5 · Accepted 2024-11-04 16:59:37

Key Financial Figures

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 AIM ImmunoTech Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 On November 4, 2024, AIM ImmunoTech Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 1, and launched a website, www.SafeguardAIM.com, to communicate with stockholders of the Company, screenshots and materials posted to the website are attached hereto as Exhibits 2 and 3, respectively. In addition, on November 4, 2024, the Company mailed a timeline of events detailing significant contacts between the Company and members of the dissident group to stockholders of the Company, a copy of which is attached hereto as Exhibit 4. Important Additional Information The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here . Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/. Exhibit 1 AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders Warns Shareholders that Activist Group’s Self-Interested Agenda Could Disrupt AIM’s Momentum and Destroy Chances for Near-Term Value Creation Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications Including Pancreatic Cancer Urges Shareholders to Safeguard AIM by Voting “FOR” ALL Four of the Board’s Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Visit www.SafeguardAIM.com for More Information OCALA, Fla. , November 4, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual Meeting of Stockholders, scheduled for December 17, 2024. The Company also mailed a letter to shareholders. The full text of the letter to shareholders follows: November 4, 2024 Dear Fellow Shareholders: Thank you for your investment in AIM ImmunoTech Inc. (“AIM” or the “Company”). Your vote at this year’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for December 17, 2024, is critical. For the third year in a row, a group of activist investors (collectively, the “Activist Group”) has nominated a slate of nominees – which this time includes Robert L. Chioini, Todd Deutsch, Ted D. Kellner and Paul W. Sweeney – in an attempt to take control of the AIM Board of Directors (the “Board”). This year, the Activist Group – which includes individuals with checkered pas

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing